Government Of Quebec Has Expanded Public Reimbursement Of Abbott's FreeStyle Libre 2 Flash Glucose Monitoring System To More Adults With Diabetes
Government Of Quebec Has Expanded Public Reimbursement Of Abbott's FreeStyle Libre 2 Flash Glucose Monitoring System To More Adults With Diabetes
Abbott (NYSE:ABT) today announced that the Government of Quebec's Régie de l'assurance maladie du Québec (RAMQ) published an update to its formulary that includes expanded reimbursement for Abbott's FreeStyle Libre 2* flash glucose monitoring system to more adults living with type 1 and type 2 diabetes.
Abbott（纽交所：ABT）今天宣布，魁北克省保健保险局RAMQ发布了一份更新的清单，扩大了对Abbott的FreeStyle Libre 2*闪光葡萄糖检测系统的补偿范围，使更多罹患1型和2型糖尿病的成年人受益。
As of July 4, 2024, provincial reimbursement criteria expanded for individuals 18 years of age and older with type 1 or type 2 diabetes who are treated with intensive insulin to include those who also meet one or more of the following criteria: Those who have not been able to achieve their targeted hemoglobin A1c (HbA1c) or who are unable to recognize or report symptoms of hypoglycemia.
截至2024年7月4日，省级补偿标准扩大到18岁及以上的使用高强度胰岛素治疗的1型或2型糖尿病患者，包括那些还符合以下一个或多个标准的人：未能达到其目标的糖化血红蛋白（HbA1c）或无法识别或报告低血糖症状的患者。
